GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
M

Maccura Biotechnology Co 300463.SZ · CNY

Health Care · Shenzhen · 🇨🇳 China

Compare

8.96

-1.10%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥2.17bn

FY2016FY2025

Net income

−CN¥35.8m

FY2016FY2025

Free cash flow

−CN¥146.7m

FY2016FY2025

Shareholders' equity

CN¥6.28bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥2.17bnCN¥2.55bnCN¥2.90bnCN¥3.61bnCN¥3.98bnCN¥3.70bnCN¥3.22bnCN¥2.69bnCN¥1.97bnCN¥1.49bn
Gross profitCN¥1.28bnCN¥1.38bnCN¥1.51bnCN¥1.90bnCN¥2.24bnCN¥1.91bnCN¥1.63bnCN¥1.37bnCN¥1.05bnCN¥802.5m
Research and developmentCN¥317.9mCN¥323.2mCN¥324.2mCN¥273.2mCN¥207.3mCN¥202.1mCN¥140.1mCN¥108.8mCN¥87.5mCN¥72.6m
Operating incomeCN¥54.8mCN¥170.0mCN¥331.1mCN¥817.4mCN¥1.21bnCN¥989.7mCN¥695.8mCN¥598.2mCN¥508.0mCN¥402.1m
Net income−CN¥35.8mCN¥126.8mCN¥312.6mCN¥708.2mCN¥956.6mCN¥793.9mCN¥525.3mCN¥444.9mCN¥374.1mCN¥312.0m
Diluted earnings per share-0.060.210.511.161.611.430.950.790.670.54

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥7.99bnCN¥7.98bnCN¥8.12bnCN¥8.16bnCN¥6.57bnCN¥6.36bnCN¥5.50bnCN¥4.56bnCN¥3.58bnCN¥2.70bn
Cash and short-term investments—CN¥731.5mCN¥1.15bnCN¥1.25bnCN¥637.2mCN¥612.1mCN¥443.9mCN¥441.6mCN¥344.4mCN¥153.9m
Total liabilitiesCN¥1.69bnCN¥1.55bnCN¥1.51bnCN¥1.63bnCN¥2.03bnCN¥2.36bnCN¥2.17bnCN¥1.69bnCN¥970.1mCN¥415.0m
DebtCN¥521.9mCN¥446.0mCN¥320.1mCN¥701.2mCN¥1.12bnCN¥1.32bnCN¥1.51bnCN¥1.19bnCN¥669.5mCN¥198.7m
Shareholders' equityCN¥6.28bnCN¥6.37bnCN¥6.38bnCN¥6.29bnCN¥4.30bnCN¥3.80bnCN¥3.13bnCN¥2.70bnCN¥2.50bnCN¥2.24bn
Shares outstanding612m613m612m612m594m556m552m563m555m577m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥602.3mCN¥633.8mCN¥912.1mCN¥843.2mCN¥1.62bnCN¥1.09bnCN¥459.5mCN¥193.9mCN¥79.0mCN¥49.3m
Capital spending−CN¥749.1m−CN¥963.0m−CN¥877.9m−CN¥987.7m−CN¥601.8m−CN¥501.3m−CN¥504.7m−CN¥529.9m−CN¥462.4m−CN¥388.7m
Free cash flow−CN¥146.7m−CN¥329.2mCN¥34.2m−CN¥144.5mCN¥1.01bnCN¥592.7m−CN¥45.2m−CN¥336.0m−CN¥383.3m−CN¥339.4m
Dividends paid−CN¥83.7m−CN¥115.2m−CN¥244.6m−CN¥286.6m−CN¥238.4m−CN¥105.4m−CN¥89.3m−CN¥122.8m−CN¥77.0m−CN¥54.1m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥558.8mCN¥475.3mCN¥562.6mCN¥532.9mCN¥564.8mCN¥510.3mCN¥601.1mCN¥668.7m
Gross profitCN¥317.9mCN¥274.4mCN¥380.5mCN¥287.1mCN¥313.2mCN¥289.6mCN¥262.1mCN¥397.3m
Operating incomeCN¥35.6mCN¥17.3m−CN¥62.8mCN¥6.9mCN¥21.1mCN¥34.5m−CN¥184.6mCN¥94.5m
Net incomeCN¥25.3mCN¥9.0m−CN¥72.9mCN¥3.1mCN¥10.1mCN¥24.0m−CN¥154.6mCN¥79.6m
Diluted earnings per share0.040.01-0.120.010.020.04-0.250.13
Cash from operations———CN¥148.0mCN¥106.0mCN¥55.0mCN¥140.0mCN¥281.0m
Capital spending−CN¥109.0m−CN¥125.0m−CN¥213.0m−CN¥176.0m−CN¥185.0m−CN¥173.0m−CN¥224.0m−CN¥274.0m
Free cash flow———−CN¥28.0m−CN¥79.0m−CN¥118.0m−CN¥84.0mCN¥7.0m
Total assetsCN¥7.82bnCN¥7.99bnCN¥7.99bnCN¥7.99bnCN¥8.01bnCN¥8.06bnCN¥7.98bnCN¥8.21bn
Cash and short-term investments———CN¥725.0mCN¥710.2mCN¥772.1mCN¥731.5mCN¥950.0m
DebtCN¥592.6mCN¥555.8mCN¥521.9mCN¥504.1mCN¥828.5mCN¥621.7mCN¥439.2mCN¥483.4m
Shareholders' equityCN¥6.31bnCN¥6.28bnCN¥6.28bnCN¥6.33bnCN¥6.32bnCN¥6.38bnCN¥6.37bnCN¥6.54bn

Financial ratios

Data as of 11 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin59.0%54.0%52.2%52.6%56.3%51.5%
Operating margin-3.6%10.3%11.5%22.6%31.2%27.7%
Net margin-1.7%5.0%10.8%19.6%24.0%21.4%
Return on equity-0.6%2.0%4.9%11.3%22.3%20.9%
Return on assets-0.4%1.6%3.9%8.7%14.6%12.5%
Free cash flow yield23.0%27.2%30.5%31.2%39.0%29.9%
Revenue growth-14.8%-12.0%-19.7%-9.4%7.5%14.9%
Earnings growth-128.3%-59.4%-55.9%-26.0%20.5%51.1%
Current ratio3.06x3.04x3.77x4.34x2.94x2.24x
Debt to equity0.08x0.07x0.05x0.11x0.22x0.33x
Equity ratio78.5%79.8%78.6%77.1%65.5%59.6%
Interest coverage-3.62x11.38x9.63x22.89x20.44x14.71x
R&D as a share of sales14.6%12.7%11.2%7.6%5.2%5.5%
Buybacks as a share of market value0.1%-0.0%0.0%-3.1%-6.7%-0.7%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-15.6%-10.1%7.4%
Operating income-59.4%-43.9%-15.7%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin56.3%54.0%54.0%53.4%
Operating margin4.8%12.2%18.9%20.7%
Net margin1.9%9.9%15.1%16.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings-191.263.829.515.018.132.628.418.535.545.4
Price to sales3.23.23.22.94.37.04.63.16.89.5

Dividends and splits

Per share, in the currency the company pays

Paid for 10 years. Last went ex-dividend on 28 May 2025.

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Paid in the year0.1040.1540.3490.4710.4310.1890.160.136
  • 3-for-1 split · 8 Jun 2016

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.